title: FDA reversal sends mixed message to multiple sclerosis community.
authors.forename: Elie
authors.initials: E
authors.lastname: Dolgin
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000453:epidemiology; D012111:Residence Characteristics; D014481:United States; D014486:United States Food and Drug Administration / Q000331:legislation & jurisprudence*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074323:Alemtuzumab